Literature DB >> 29709315

Salvage HDR Brachytherapy: Multiple Hypothesis Testing Versus Machine Learning Analysis.

Gilmer Valdes1, Albert J Chang2, Yannet Interian3, Kenton Owen2, Shane T Jensen4, Lyle H Ungar5, Adam Cunha2, Timothy D Solberg2, I-Chow Hsu2.   

Abstract

PURPOSE: Salvage high-dose-rate brachytherapy (sHDRB) is a treatment option for recurrences after prior radiation therapy. However, only approximately 50% of patients benefit, with the majority of second recurrences after salvage brachytherapy occurring distantly. Therefore, identification of characteristics that can help select patients who may benefit most from sHDRB is critical. Machine learning may be used to identify characteristics that predict outcome following sHDRB. We aimed to use machine learning to identify patient characteristics associated with biochemical failure (BF) following prostate sHDRB. METHODS AND MATERIALS: We analyzed data for 52 patients treated with sHDRB for locally recurrent prostate cancer after previous definitive radiation therapy between 1998 and 2009. Following pathologic confirmation of locally recurrent disease without evidence of metastatic disease, 36 Gy in 6 fractions was administered to the prostate and seminal vesicles. BF following sHDRB was defined using the Phoenix definition. Sixteen different clinical risk features were collected, and machine learning analysis was executed to identify subpopulations at higher risk of BF. Decision tree-based algorithms including classification and regression trees, MediBoost, and random forests were constructed.
RESULTS: Patients were followed up for a minimum of 5 years after sHDRB. Those with a fraction of positive cores ≥0.35 and a disease-free interval <4.12 years after their initial radiation treatment experienced a higher failure rate after sHDRB of 0.75 versus 0.38 for the rest of the population.
CONCLUSIONS: Using machine learning, we have identified that patients with a fraction of positive cores ≥0.35 and a disease-free interval <4.1 years might be associated with a high risk of BF following sHDRB.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29709315     DOI: 10.1016/j.ijrobp.2018.03.001

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

Review 1.  Artificial intelligence (AI) and interventional radiotherapy (brachytherapy): state of art and future perspectives.

Authors:  Bruno Fionda; Luca Boldrini; Andrea D'Aviero; Valentina Lancellotta; Maria Antonietta Gambacorta; György Kovács; Stefano Patarnello; Vincenzo Valentini; Luca Tagliaferri
Journal:  J Contemp Brachytherapy       Date:  2020-10-30

Review 2.  Artificial intelligence and machine learning for medical imaging: A technology review.

Authors:  Ana Barragán-Montero; Umair Javaid; Gilmer Valdés; Dan Nguyen; Paul Desbordes; Benoit Macq; Siri Willems; Liesbeth Vandewinckele; Mats Holmström; Fredrik Löfman; Steven Michiels; Kevin Souris; Edmond Sterpin; John A Lee
Journal:  Phys Med       Date:  2021-05-09       Impact factor: 2.685

Review 3.  Artificial intelligence in brachytherapy: a summary of recent developments.

Authors:  Susovan Banerjee; Shikha Goyal; Saumyaranjan Mishra; Deepak Gupta; Shyam Singh Bisht; Venketesan K; Kushal Narang; Tejinder Kataria
Journal:  Br J Radiol       Date:  2021-04-29       Impact factor: 3.629

4.  Development of a Machine Learning Model for Optimal Applicator Selection in High-Dose-Rate Cervical Brachytherapy.

Authors:  Kailyn Stenhouse; Michael Roumeliotis; Robyn Banerjee; Svetlana Yanushkevich; Philip McGeachy
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.